BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22460425)

  • 1. LKB1, TP16, EGFR, and KRAS somatic mutations in lung adenocarcinomas from a Chiba Prefecture, Japan cohort.
    Suzuki Y; Oonishi T; Kudo T; Doi H
    Drug Discov Ther; 2012 Feb; 6(1):24-30. PubMed ID: 22460425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas.
    Gao B; Sun Y; Zhang J; Ren Y; Fang R; Han X; Shen L; Liu XY; Pao W; Chen H; Ji H
    J Thorac Oncol; 2010 Aug; 5(8):1130-5. PubMed ID: 20559149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
    Gao J; Chen JQ; Zhang L; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.
    Bacchi CE; Ciol H; Queiroga EM; Benine LC; Silva LH; Ojopi EB
    Clinics (Sao Paulo); 2012; 67(5):419-24. PubMed ID: 22666783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
    Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
    Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LKB1 gene alterations in surgically resectable adenocarcinoma of the lung.
    Okuda K; Sasaki H; Hikosaka Y; Kawano O; Moriyama S; Yano M; Fujii Y
    Surg Today; 2011 Jan; 41(1):107-10. PubMed ID: 21191700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
    Sun Y; Ren Y; Fang Z; Li C; Fang R; Gao B; Han X; Tian W; Pao W; Chen H; Ji H
    J Clin Oncol; 2010 Oct; 28(30):4616-20. PubMed ID: 20855837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.
    D'Angelo SP; Park B; Azzoli CG; Kris MG; Rusch V; Ladanyi M; Zakowski MF
    J Thorac Cardiovasc Surg; 2011 Feb; 141(2):476-80. PubMed ID: 20933246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in Korean patients with lung adenocarcinoma.
    Kim HR; Ahn JR; Lee JG; Bang DH; Ha SJ; Hong YK; Kim SM; Nam KC; Rha SY; Soo RA; Riely GJ; Kim JH; Cho BC
    Yonsei Med J; 2013 Jul; 54(4):865-74. PubMed ID: 23709419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.
    Sonobe M; Kobayashi M; Ishikawa M; Kikuchi R; Nakayama E; Takahashi T; Menju T; Takenaka K; Miyahara R; Huang CL; Okubo K; Bando T; Date H
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S347-54. PubMed ID: 21607772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
    Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
    Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.
    Kaufman JM; Amann JM; Park K; Arasada RR; Li H; Shyr Y; Carbone DP
    J Thorac Oncol; 2014 Jun; 9(6):794-804. PubMed ID: 24828662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa).
    Fu M; Zhang W; Shan L; Song J; Shang D; Ying J; Zhao J
    Virchows Arch; 2014 May; 464(5):575-81. PubMed ID: 24595526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
    Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study.
    Bircan S; Baloglu H; Kucukodaci Z; Bircan A
    Med Oncol; 2014 Aug; 31(8):87. PubMed ID: 24973952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.
    Koivunen JP; Kim J; Lee J; Rogers AM; Park JO; Zhao X; Naoki K; Okamoto I; Nakagawa K; Yeap BY; Meyerson M; Wong KK; Richards WG; Sugarbaker DJ; Johnson BE; Jänne PA
    Br J Cancer; 2008 Jul; 99(2):245-52. PubMed ID: 18594528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans.
    Reinersman JM; Johnson ML; Riely GJ; Chitale DA; Nicastri AD; Soff GA; Schwartz AG; Sima CS; Ayalew G; Lau C; Zakowski MF; Rusch VW; Ladanyi M; Kris MG
    J Thorac Oncol; 2011 Jan; 6(1):28-31. PubMed ID: 21107288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
    Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ
    Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.
    Borràs E; Jurado I; Hernan I; Gamundi MJ; Dias M; Martí I; Mañé B; Arcusa A; Agúndez JA; Blanca M; Carballo M
    BMC Cancer; 2011 Sep; 11():406. PubMed ID: 21943394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.